Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Rybelsus, semaglutide-maker Novo Nordisk's GLP-1 pill, brute forces its way around this with larger doses, but requires specific dietary instructions and doesn't seem to be as effective for weight ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a diabetes treatment since 2019. It's an orally available version of ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

When taken for 40 weeks for type 2 diabetes, orforglipron resulted in an average loss of 16 pounds, or about 7.9% of the patient's body weight, at the highest dose. HealthDay News — A new pill ...

If you're one of the many people who have been interested in Ozempic-style weight loss medications but are terrified of ...

It positions the pharma to dominate the oral GLP-1 market. The pill achieved 7.9% weight loss (16 pounds) and 1.3% to 1.6% A1C reduction in diabetes patients over 40 weeks, rivaling Novo Nordisk ...

The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed ...